Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Hepatocellular Carcinoma | Research article

Distinct molecular etiologies of male and female hepatocellular carcinoma

Authors: Heini M. Natri, Melissa A. Wilson, Kenneth H. Buetow

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Sex-differences in cancer occurrence and mortality are evident across tumor types; men exhibit higher rates of incidence and often poorer responses to treatment. Targeted approaches to the treatment of tumors that account for these sex-differences require the characterization and understanding of the fundamental biological mechanisms that differentiate them. Hepatocellular Carcinoma (HCC) is the second leading cause of cancer death worldwide, with the incidence rapidly rising. HCC exhibits a male-bias in occurrence and mortality, but previous studies have failed to explore the sex-specific dysregulation of gene expression in HCC.

Methods

Here, we characterize the sex-shared and sex-specific regulatory changes in HCC tumors in the TCGA LIHC cohort using combined and sex-stratified differential expression and eQTL analyses.

Results

By using a sex-specific differential expression analysis of tumor and tumor-adjacent samples, we uncovered etiologically relevant genes and pathways differentiating male and female HCC. While both sexes exhibited activation of pathways related to apoptosis and cell cycle, males and females differed in the activation of several signaling pathways, with females showing PPAR pathway enrichment while males showed PI3K, PI3K/AKT, FGFR, EGFR, NGF, GF1R, Rap1, DAP12, and IL-2 signaling pathway enrichment. Using eQTL analyses, we discovered germline variants with differential effects on tumor gene expression between the sexes. 24.3% of the discovered eQTLs exhibit differential effects between the sexes, illustrating the substantial role of sex in modifying the effects of eQTLs in HCC. The genes that showed sex-specific dysregulation in tumors and those that harbored a sex-specific eQTL converge in clinically relevant pathways, suggesting that the molecular etiologies of male and female HCC are partially driven by differential genetic effects on gene expression.

Conclusions

Sex-stratified analyses detect sex-specific molecular etiologies of HCC. Overall, our results provide new insight into the role of inherited genetic regulation of transcription in modulating sex-differences in HCC etiology and provide a framework for future studies on sex-biased cancers.

Available only for authorised users

Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16:330.CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21492.

Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol. 2007;25:1705–12.CrossRefPubMed

OuYang P-Y, Zhang L-N, Lan X-W, Xie C, Zhang W-W, Wang Q-X, et al. The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer. 2015;112:1554–61.CrossRefPubMedPubMedCentral

Li CH, Haider S, Shiah Y-J, Thai K, Boutros PC. Sex differences in Cancer driver genes and biomarkers. Cancer Res. 2018;78:5527–37.CrossRefPubMed

Wands J. Hepatocellular carcinoma and sex. N Engl J Med. 2007;357:1974–6.CrossRefPubMed

Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139:1534–45.CrossRefPubMedPubMedCentral

Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-Centre cohort study. BMJ Open Gastroenterol. 2016;3:e000107.CrossRefPubMedPubMedCentral

Gilks WP, Abbott JK, Morrow EH. Sex differences in disease genetics: evidence, evolution, and detection. Trends Genet. 2014;30:453–63.CrossRefPubMed

10.

Morrow EH. The evolution of sex differences in disease. Biol Sex Differ. 2015;6:5.CrossRefPubMedPubMedCentral

11.

Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in Cancer between male and female patients. Cancer Cell. 2016;29:711–22.CrossRefPubMedPubMedCentral

12.

Gong J, Mei S, Liu C, Xiang Y, Ye Y, Zhang Z, et al. PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 2018;46:D971–6.CrossRefPubMed

13.

Behrens G, Winkler TW, Gorski M, Leitzmann MF, Heid IM. To stratify or not to stratify: power considerations for population-based genome-wide association studies of quantitative traits. Genet Epidemiol. 2011;35:867–79.CrossRefPubMed

14.

Dimas AS, Nica AC, Montgomery SB, Stranger BE, Raj T, Buil A, et al. Sex-biased genetic effects on gene regulation in humans. Genome Res. 2012;22:2368–75.CrossRefPubMedPubMedCentral

15.

Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for Cancer genomic data. N Engl J Med. 2016;375:1109–12.CrossRefPubMedPubMedCentral

16.

Webster TH, Couse M, Grande BM, Karlins E, Phung TN, Richmond PA, et al. Identifying, understanding, and correcting technical biases on the sex chromosomes in next-generation sequencing data [Internet]. bioRxiv. 2018. p. 346940. doi:https://doi.org/10.1101/346940

17.

Andrews S. FastQC A Quality Control tool for High Throughput Sequence Data. In: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ [Internet]. 2010. Available: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/

18.

Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.CrossRefPubMedPubMedCentral

19.

Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60.CrossRefPubMedPubMedCentral

20.

Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.CrossRefPubMed

21.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.CrossRefPubMedPubMedCentral

22.

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.CrossRefPubMedPubMedCentral

23.

Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:11.10.1–33.

24.

Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC genome browser database: update 2006. Nucleic Acids Res. 2006;34:D590–8.CrossRefPubMed

25.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.CrossRefPubMed

26.

Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.CrossRefPubMedPubMedCentral

27.

Xia J, Gill EE, Hancock REW. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc. 2015;10:823–44.CrossRefPubMed

28.

Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:e161.CrossRefPubMedCentral

29.

Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 2012;7:500–7.CrossRefPubMedPubMedCentral

30.

Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics. 2012;28:3326–8.CrossRefPubMedPubMedCentral

31.

Delaneau O, Ongen H, Brown AA, Fort A, Panousis N, Dermitzakis E. A complete tool set for molecular QTL discovery and analysis. bioRxiv. 2016; doi:https://doi.org/10.1101/068635.

32.

GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–5.CrossRef

33.

Cavalcante RG, Sartor MA. Annotatr: genomic regions in context. Bioinformatics. 2017;33:2381–3.CrossRefPubMedPubMedCentral

34.

Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215–6.CrossRefPubMedPubMedCentral

35.

Kukurba KR, Parsana P, Balliu B, Smith KS, Zappala Z, Knowles DA, et al. Impact of the X chromosome and sex on regulatory variation. Genome Res. 2016;26:768–77.CrossRefPubMedPubMedCentral

36.

Gho JW-M, Ip W-K, Chan KY-Y, Law PT-Y, Lai PB-S, Wong N. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest. Cancer Res. 2008;68:6743–51.CrossRefPubMed

37.

Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104:1523–31.CrossRefPubMedPubMedCentral

38.

Shen Y, Li X, Su Y, Badshah SA, Zhang B, Xue Y, et al. HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway [Internet]. Diagnostics. 2019. p. 48. doi:https://doi.org/10.3390/diagnostics9020048

39.

Liu F, Zhu C, Huang X, Cai J, Wang H, Wang X, et al. A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival. Pathol Res Pract. 2014;210:885–92.CrossRefPubMed

40.

Jo J-C, Choi EK, Shin J-S, Moon J-H, Hong S-W, Lee H-R, et al. Targeting FGFR pathway in human hepatocellular carcinoma: expressing pFGFR and pMET for antitumor activity. Mol Cancer Ther. 2015;14:2613–22.CrossRefPubMed

41.

Xiao P, Long X, Zhang L, Ye Y, Guo J, Liu P, et al. Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of tumor-associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. Oncoimmunology. 2018;7:e1440166.CrossRefPubMedPubMedCentral

42.

Lasseigne BN, Burwell TC, Patil MA, Absher DM, Brooks JD, Myers RM. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med. 2014;12:235.CrossRefPubMedPubMedCentral

43.

Gaykalova DA, Zizkova V, Guo T, Tiscareno I, Wei Y, Vatapalli R, et al. Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC. Oncotarget. 2017;8:15349–63.CrossRefPubMedPubMedCentral

44.

Liu Y, Zheng P. CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol. 2007;28:315–20.CrossRefPubMed

45.

Gou Q, Gong X, Jin J, Shi J, Hou Y. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget. 2017;8:60704–9.PubMedPubMedCentral

46.

Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for Cancer treatment. Annu Rev Med. 2016;67:11–28.CrossRefPubMed

47.

Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, et al. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hematol. 2017;113:256–67.CrossRefPubMed

48.

Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31.CrossRefPubMedPubMedCentral

49.

Demir IE, Tieftrunk E, Schorn S, Friess H, Ceyhan GO. Nerve growth factor & TrkA as novel therapeutic targets in cancer. Biochim Biophys Acta. 1866;2016:37–50.

50.

Zhang Y-L, Wang R-C, Cheng K, Ring BZ, Su L. Roles of Rap1 signaling in tumor cell migration and invasion. Cancer Biol Med. 2017;14:90–9.CrossRefPubMedPubMedCentral

51.

Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in Cancer immunotherapy. Biomed Res Int. 2018;2018:9056173.CrossRefPubMedPubMedCentral

52.

Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.CrossRefPubMed

53.

Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473–510.CrossRefPubMedPubMedCentral

54.

Mehta A, Herrera H, Block T. Chapter Seven - Glycosylation and Liver Cancer. In: Drake RR, Ball LE, editors. Advances in Cancer Research. Cambridge: Academic Press; 2015. pp. 257–279.

55.

Liang K-H, Yeh C-T. O-glycosylation in liver cancer: clinical associations and potential mechanisms. Liver Res. 2017;1:193–6.CrossRef

56.

Villegas SN, Gombos R, García-López L, Gutiérrez-Pérez I, García-Castillo J, Vallejo DM, et al. PI3K/Akt cooperates with oncogenic notch by inducing nitric oxide-dependent inflammation. Cell Rep. 2018;22:2541–9.CrossRefPubMed

57.

Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010;29:2488–98.CrossRefPubMedPubMedCentral

58.

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24:766–76.CrossRefPubMed

59.

Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia [Internet]. Cellular Signalling. 2014. pp. 149–161. doi:https://doi.org/10.1016/j.cellsig.2013.09.021

60.

Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 2011;7:787–93.CrossRefPubMedPubMedCentral

61.

Wang G-L, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004;18:912–25.CrossRefPubMedPubMedCentral

62.

Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483–96.CrossRefPubMedPubMedCentral

63.

Baar EL, Carbajal KA, Ong IM, Lamming DW. Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging Cell. 2016;15:155–66.CrossRefPubMed

Title: Distinct molecular etiologies of male and female hepatocellular carcinoma
Authors: Heini M. Natri
Melissa A. Wilson
Kenneth H. Buetow
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-6167-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

A modified subclassification to evaluate the survival of patients with N3 gastric cancer: an international database study

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Impact of [64Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report

Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report

Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer